CLAIMS

1. An allogeneic composition comprising Vδ1+ T cells for use in the treatment of a patient with a myeloid malignancy, wherein the patient is positive for minimal residual disease (MRD+).

2. The allogeneic composition for use as defined in claim 1, wherein the myeloid malignancy is selected from acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS).

3. The allogeneic composition for use as defined in claim 1 or 2, wherein the MRD+ patient is in complete remission, contains no detectable leukaemic blasts in the peripheral blood and contains less than 5% leukaemic blasts in the bone marrow.

4. The allogeneic composition for use as defined in any one of claims 1 to 3, wherein the patient has previously been treated with chemotherapy.

5. The allogeneic composition for use as defined in claim 4, wherein the patient has been treated with chemotherapy at least 3 days prior to administration of the allogeneic composition.

6. The allogeneic composition for use as defined in claim 4 or claim 5, wherein the chemotherapy is selected from fludarabine and cyclophosphamide.

7. The allogeneic composition for use as defined in any one of claims 1 to 6, which comprises at least 90% CD45+ cells relative to total live cells.

8. The allogeneic composition for use as defined in any one of claims 1 to 7, which comprises at least 60% γδ T cells relative to total live cells.

9. The allogeneic composition for use as defined in any one of claims 1 to 8, which comprises at least 50% Vδ1+ T cells relative to total live cells.

10. The allogeneic composition for use as defined in any one of claims 1 to 9, wherein the allogeneic composition comprises 8×10^9, 4×10^9, 2.4×10^9, 1.2×10^9, 8×10^8, 4×10^8, 8×10^7 or 4×10^7 total live cells.

11. The allogeneic composition for use of any one of claims 1 to 9, which is to be administered at a dose of 1×10^5 cells/kg.

12. The allogeneic composition for use of any one of claims 1 to 9, which is to be administered at a dose of 1×10^6 cells/kg.

13. The allogeneic composition for use of any one of claims 1 to 9, which is to be administered at a dose of 1×10^7 cells/kg.

14. The allogeneic composition for use of any one of claims 1 to 9, which is to be administered at a dose of 3×10^7 cells/kg.

15. The allogeneic composition for use of any one of claims 1 to 9, which is to be administered at a dose of 1×10^8 cells/kg.

16. The allogeneic composition for use of any one of claims 1 to 9, which is to be administered at a dose that comprises 5×10^4 αβ T cells/kg.

17. The allogeneic composition for use of any one of claims 1 to 9, which is to be administered at a dose that comprises 1×10^4 αβ T cells/kg.

18. The allogeneic composition for use as defined in any one of claims 1 to 17, wherein the Vδ1+ T cells are obtained from a sample by a method comprising culturing the sample in a medium comprising a T cell mitogen and a growth factor having interleukin-4-like activity, in the absence of a growth factor having interleukin-15-like activity.

19. The allogeneic composition for use as defined in any one of claims 1 to 17, wherein the Vδ1+ T cells are obtained from a sample by a method comprising culturing the sample in a medium comprising a T cell mitogen and a growth factor having interleukin-15-like activity, in the absence of a growth factor having interleukin-4-like activity.

20. The allogeneic composition for use as defined in claim 18 or claim 19, wherein the Vδ1+ T cells are collected after at least 11 days of culturing.

21. The allogeneic composition for use as defined in any one of claims 18 to 20, wherein the culturing is performed in a vessel comprising a gas permeable material.

22. The allogeneic composition for use as defined in claim 21, wherein the vessel comprises a liquid sealed container comprising a gas permeable material to allow gas exchange.

23. The allogeneic composition for use as defined in claim 21 or claim 22, wherein the bottom of said vessel is configured to allow gas exchange from the bottom of the vessel.

24. The allogeneic composition for use as defined in any one of claims 18 to 23, wherein the sample is cultured in serum-free medium.

25. The allogeneic composition for use as defined in any one of claims 18 to 23, wherein the sample is cultured in media containing serum or serum-replacement.